Depressing AAPL and Geron down, ACTC up on good news

What a depressing market. AAPL down down down to $537.75 on alot of volume 37.7 million shares. The three month avg. is 17.6 million shares. AAPL is still the best company out there, for now, makes you think what in the world is going on. ..................................................................................................................................................................................................................................................................... Geron down to $1.28 I can only hope Dec. will being good results the the last 4 trials. If I will be sitting here crying........................................ ..................................................................................................................................................................................................................................................................... ACTC had good news on was up a little at 0.072. Advanced Cell Tech. announces interim data from its three ongoing macular degeneration trials; no adverse safety issues relating to the transplanted cells have been observed (ACTC) 0.07 +0.00 : Co announced that its upcoming conference call on its third quarter financial results will also provide some representative examples of data being collected from patients in its clinical trials for forms of macular degeneration. The Company has treated 13 patients thus far in its three ongoing trials for dry age-related macular degeneration (dry AMD) and Stargardt's Disease (SMD) using human embryonic stem cell (hESC)-derived retinal pigment epithelial cells. The first two trials were initiated in July of 2011. Across the various clinical trial sites, with regular patient follow-up, no adverse safety issues relating to the transplanted cells have been observed. At up to 16 months following treatment, no hyperproliferation, tumorigenicity, ectopic tissue formation, or apparent rejection were observed in any of the 13 patients at any time. At a recent meeting of the various U.S. and U.K. surgeons leading the clinical trials, the Company and surgeons reviewed the data from various patients and discussed next steps and strategies for the existing trials and designs for future phase II and III studies..............................................I still have a good feeling about this company. It's a very, very long shot.............................................. .............................................................................................................................................................................. Good luck in this rigged casino,

Geron and AAPL killing me

Geron down 6 cent to close at $1.31 on only 453,489 the ten day avg is 789,925 shares. Waited for Phase two trial results in early Dec. Again this will make or break this company............................................................................... ..................................................................................................................................................................................................................................................................... AAPL is a big disappointment, didn't hold $600 and may go to $550. Closed down a little at $582.85. Christmas may save AAPL............................................. ..................................................................................................................................................................................................................................................................... ACTC up over 7 cents to closed at 0.0727 on 5.8 million shares the ten day avg is 4.4 million shares. Still feel this company will make it big, with little luck............ ..................................................................................................................................................................................................................................................................... Good luck in this rigged casino,

Geron good article by Ivan Deryigin

I could have sold my shares in September and walked away with profits of almost 70%, and that would have been the end of it. However, I chose not to do that. And the reason is simple. This was, and is, an investment only for risk tolerant investors, who have room for speculation in their portfolios. And I consider this investment to be, at the moment, a speculative one. When I wrote my original article, I stated that Geron has the potential to change the way that cancer is treated, due to its focus on telomerase inhibition and brain tumors. I stand by that opinion. The failure of imetelstat in solid tumors has not affected the company`s hematologic trials, nor has it affected the development of GRN-1005, which has the potential to create a truly effective treatment for brain metastases, something that has eluded cancer researchers and pharmaceutical companies for years, due to the blood-brain barrier and the difficulty of getting cancer medications across it. While Geron does have the potential to change the way that cancer is treated, the path ahead is an uncertain one, and this stock is not meant for all investors. But, for investors who are willing to take the risk, Geron continues to offer the opportunity for profits, with the next catalyst just a month away. Above is a small part of the article. This is the guy who pumped it up in Sept. up to $2.99. I hope he can do it again. With good results we should go to $3, with poor results it's all over. Geron is up 7 cents on this article. Good luck in this rigged casino,

All down ACTC AAPL Geron

Bad day, AAPL down big closing at $576.80, ACTC down under 7 cents, and Geron down 7 cents at $1.32......., ............................................................... ............................................................................................................................................................................. Nothing good will happen till after the election and the fiscal cliff is fixed......... .................................................................................................................................................................................................................................................................... Good luck in this rigged casino,

Geron up, ACTC up and AAPL up

Geron was up 6 cents on very light volume only 560,143 shares. The three month avg is 1.6 million shares. Remember Chip said in a few days Geron will file a SEC 10-K report on the BioTime deal. BioTime was down 14 cents to $3.67 just a week ago it was over $4. The volume was 2xs the normal. Based on BioTime's price drop and volume I'm thinking Geron may take the deal, I hope GE makes a offer. Time was tell. ..................................................................................................................................................................................................................................................................... ACTC closed at 7 cents on avg. volume. Still waiting on results of Phase 1/2 trials should be in 3 to 6 months. .................................................................................................................................................................................................................................................................... AAPL up just a little to close at $596.54. Hoping people buy 10 million mini Ipods for the holidays......................................................................... ..............................................................................................................................................................................Good luck in this rigged casino,

Geron Earning Call

Well I read the earnings call and learned next to nothing. Upset about no infor on the stell cell deal. Chip did say in a few days will file a SEC 10-K about the BioTime deal. Chip said reports of Phase 2 trials will be coming in Dec. Again this will make or break Geron. I have no good or bad feeling about up coming reports. Good luck in this rigged casino,

ACTC gets OK for 2nd Patient Cohort in Trials for Dry AMD

Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the Company's three ongoing clinical trials, has authorized the Company to move forward with enrollment and treatment of two additional patients with dry age-related macular degeneration (dry AMD). ACT will screen and enroll the second and third patients of the three-patient second cohort in the trial. Per trial protocol, each patient will be injected with 100,000 human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells. "Dry AMD represents one of the largest unmet medical needs in the world, and we are thrilled to be making steady progress in our clinical trial for this condition," commented Gary Rabin, ACT's chairman and CEO. "We are well on our way to the halfway point of all three of our clinical trials. We also recently secured DSMB approval to complete the second cohort of our two trials for Stargardt's Macular Dystrophy." ACT is conducting three clinical trials in the U.S. and Europe using hESC-derived RPE cells to treat forms of macular degeneration, dry AMD and Stargardt's Macular Dystrophy (SMD). Each trial will enroll a total of 12 patients, with cohorts of three patients each in an ascending dosage format, from 50,000 to 200,000 hESC-derived RPE cells. These trials are prospective, open-label studies, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD or SMD at 12 months, the study's primary endpoint. "This authorization to treat the next two patients in the second, higher-dosage cohort of our trial for dry AMD represents a notable milestone for our clinical programs," commented Robert Lanza, M.D., ACT's chief scientific officer. "We look forward to treating these two patients and moving on to the third cohort in good time." Good news trials moving forward. Good luck in this rigged casino,